Mayer Hany: Recombinant Activated FVII in Spontaneous Intracerebral Hemorrhage
Mayer Hany, Volunteer at Children’s Cancer Hospital Foundation, shared a post on LinkedIn about a recent article he and his colleagues co- authored, published in Journal of Clinical Neuroscience, adding:
“Proud to share my first publication!
Our systematic review and meta-analysis on the efficacy and safety of recombinant activated factor VII in spontaneous intracerebral hemorrhage, incorporating frequentist and Bayesian approaches with GRADE assessment, has been published in the Journal of Clinical Neuroscience (Q2).
Honored to be part of this work and grateful to all my co authors.
First step in evidence based medicine.”
Title: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage
Authors: Stephan A Mayer, Nikolai C Brun, Kamilla Begtrup, Joseph Broderick, Stephen Davis, Michael N Diringer, Brett E Skolnick, Thorsten Steiner
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?